Transcriptomics

Dataset Information

LNCAP/AR and a LnCAP/AR subline (LREX') with acquired resistance to 2nd generation antiandrogens


ABSTRACT: The treatment of advanced prostate cancer has been transformed by novel antiandrogen therapies such as enzalutamide. Using the LnCaP/AR xenograft model, we identified induction of glucocorticoid receptor (GR) expression as a common feature of drug resistant tumors. From a resistant xenograft tumor, we derived a GR expressing resistant subline called LREX' which maintains the resistant phenotype. mRNA expression was used to characterize resistant tissues.

ORGANISM(S): Homo sapiens

PROVIDER: GSE51873 | GEO | 2013/12/27

SECONDARY ACCESSION(S): PRJNA225675

REPOSITORIES: GEO